Non-hormonal Medical Device for Treatment of Vulvovaginal Atrophy (VVA) in Post-Menopausal Women

Inclusion Criteria: * Women with menopause defined by last menstrual period at least 12 months prior to screening, or 6 months of amenorrhea with serum FSH levels \> 40 mIU/ml, or 8 weeks postsurgical bilateral oophorectomy with or without hysterectomy. * Sexually active women. * Participant experiencing subjective moderate-to-severe vaginal pain with sexual intercourse. * Participant experiencing subjective moderate-to-severe vaginal dryness. * Gynecological exam confirming vaginal atrophy. * Willingness to give voluntary written informed consent to participate in the study and comply with protocol requirements. Exclusion Criteria: * Use of systemic or local estrogen therapy, currently or in the last 6 months or planned use during the study. * Use of any other treatment for vaginal atrophy, 6 weeks prior to enrollment or planned during the study period. * Investigational drugs and also prescription and nonprescription medications/remedies known to treat VVA within 60 days of enrollment or during the study. * Vaginal stenosis. * Pelvic floor disorders. * Prior pelvic radiation therapy including radiation or surgery to the vulva/vagina. * Active urinary tract, yeast, or other active gynecologic infections. * Active connective tissue disorders such as lupus or Sjogren's syndrome. * Active malignancies. * Diagnosis of vulvodynia or other pelvic pain in the vagina or vulvar area. * Vulvar dermatoses. * Laser or radio frequency vaginal rejuvenation treatment or planned treatment during the study. * Any medical condition that, in the investigator's opinion, would interfere with their participation and/or completion in the study.